Clinical trials: Myeloma, Plasma-Cell
Multiple Myeloma
Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells
Patients with Multiple myeloma who have undergone non-myeloablative allogeneic stem cell transplant will receive 6 vaccinations of donor derived dendritic cells combined with specific protein produced by multiple myeloma.
- Trial name
- NCT00186316
- Testing
- Idiotype-pulsed allogeneic dendritic cells
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Multiple Myeloma
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
This is a randomized, open label, multicenter clinical trial to compare the efficacy and safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and dexamethasone versus Velcade, melphalan, and prednisone in…
- Trial name
- UPFRONT (NCT00507416)
- Testing
- Bortezomib, Dexamethasone, Melphalan
- Where
- 235 sites in United States, Puerto Rico
- Volunteers
- 502 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma, M Protein
A Cross-sectional Study on the Positive Rate of M Protein Based on a Highly Sensitive Serum M Protein Detection Method.
By using a highly sensitive serum M protein detection method based on the MALDI-TOF MS platform, serum monoclonal immunoglobul (M protein) in detection was performed on the visiting patients to explore the positive rate of serum…
- Trial name
- NCT06082284
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital
Multiple Myeloma
Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial
The present protocol aims to test, whether an approach using (i) a reduced-toxicity TBF followed by a (ii) Daratumumab maintenance and (iii) prophylactic infusion of donor lymphocytes (pDLI), will be able to improve…
- Trial name
- DARALLO (NCT04024384)
- Testing
- Daratumumab
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Myeloma and Plasma Cell Neoplasm
Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Vaccines may help the body build an effective immune response to kill cancer cells.
- Trial name
- NCT00445484
- Testing
- pneumococcal polyvalent vaccine, lenalidomide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma
Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma
This is a Phase I/IIa clinical trial to identify the maximum tolerated dose of atiprimod and to evaluate the safety of atiprimod in patients with refractory or relapsed multiple myeloma.
- Trial name
- NCT00086216
- Testing
- Atiprimod
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Callisto Pharmaceuticals
Cytokine Release Syndrome, ICANS
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor…
- Conditions
- Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma
- Trial name
- NCT04975555
- Testing
- Siltuximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery
The goal of this project is to conduct a pilot randomized clinical trial (RCT) to evaluate the feasibility of a brief, behavioral intervention to improve recovery following hematopoietic stem cell transplantation (HSCT).
- Conditions
- Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Lymphoid Leukemia
- Trial name
- NCT02955043
- Testing
- Behavioral techniques
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Wisconsin, Madison
Multiple Myeloma, Non-Hodgkin Lymphoma
Preservation of Ovarian Function After Hematopoietic Cell Transplant
Women undergoing myeloablative allogeneic hematopoietic cell transplant (MA HCT) will receive GnRH agonist leuprolide. Women undergoing reduced intensity allogeneic (RIC) HCT will be observed.
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease, Acute Myeloid Leukemia
- Trial name
- NCT01343368
- Testing
- Leuprolide, hematopoietic cell transplant, reduced intensity allogeneic HCT
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma and Plasma Cell Neoplasm
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as melphalan, prednisone, and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00477750
- Testing
- lenalidomide, melphalan, prednisone
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.
This study is a Phase Ib, open label, single arm, adaptive multi-centre clinical study. The target population for this study are patients with relapsed/refractory multiple myeloma (MM).
- Trial name
- CPD-DARA (NCT04667663)
- Testing
- Daratumumab, Cyclophosphamide, Pomalidomide
- Where
- 3 sites in Ireland
- Volunteers
- 16 people
- Sponsor
- Cancer Trials Ireland
Multiple Myeloma
A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma
This is a first in human study which will assess the safety and tolerability of a monoclonal antibody against ICAM-1 in patients with Multiple Myeloma. The tumour response rate will also be measured.
- Trial name
- NCT01025206
- Testing
- BI-505
- Where
- 7 sites in United States, Belgium and 2 more
- Volunteers
- 35 people
- Sponsor
- BioInvent International AB
Graft-versus-leukemia, Graft vs Host Disease
Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
This study will provide follow-up evaluation and care of patients who have undergone allogeneic (donor) stem cell transplantation at the NIH Clinical Center.
- Conditions
- Graft-versus-leukemia, Graft vs Host Disease, Graft Rejection
- Trial name
- NCT00106925
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Newly Diagnosed Multiple Myeloma
A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma
This study aims to evaluate the safety and efficacy of Linperlisib combined with the VRD regimen in the treatment of newly diagnosed patients with multiple myeloma.
- Trial name
- NCT06799676
- Testing
- a combination treatment of Linperlisib and the VRD regimen
- Where
- 3 sites in China
- Volunteers
- 42 people
- Sponsor
- Fuling Zhou
Newly Diagnosed Multiple Myeloma, T(11;14)
A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen
The goal of this study is to evaluate treatment of newly diagnosed multiple myeloma patients with t(11;14) suitable for transplantation using the SonKRd regimen, consisting of Sodium Thiotepa, Caffizotide, Lenalidomide, and…
- Conditions
- Newly Diagnosed Multiple Myeloma, T(11;14), Sotoclax, Carfilzomib
- Trial name
- NCT07709884
- Testing
- Sotoclax, Carfilzomib, Lenalidomide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma
Study a quadruplet-based regimen with Minimal Residual Disease (MRD) 10-5 negative rate as primary end point in patients with early Relapsed or Refractory Multiple Myeloma.
- Trial name
- NCT04287855
- Testing
- Isatuximab, Carfilzomib, Pomalidomide
- Where
- France
- Volunteers
- 82 people
- Sponsor
- Poitiers University Hospital
Relapsed, Refractory or Plateau Phase Multiple Myeloma
A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma
To evaluate the response rate (Complete Response [CR] and Partial Response [PR]) to dasatinib in patients with relapsed, refractory or plateau phase multiple myeloma whose serum paraprotein levels are >0.5g/dL or urine…
- Trial name
- NCT00429949
- Testing
- Dasatinib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Relapsed or Refractory Multiple Myeloma
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
The purpose of this study is to evaluate how well IBI3003 works when compared with the investigator's choice regimen (DPd or PVd or SVd)
- Trial name
- NCT07623798
- Testing
- Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection)
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Multiple Myeloma
Sequential High-dose Dexamethasone and Response Adopted PAD or VAD Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Complete Response (CR) plus near CR rate of VAD (Vincristine, Adriamycin, Dexamethasone) induction chemotherapy followed by ASCT in patients with newly diagnosed MM was about 50% and CR plus near CR rate of PAD (Bortezomib…
- Trial name
- NCT01255514
- Testing
- high dose dexamethsone
- Where
- 8 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Yonsei University
Multiple Myeloma
Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma
The purpose of this study is to determine the safety and tolerability of dasatinib with bortezomib in the treatment of relapsed or refractory multiple myeloma.
- Trial name
- NCT00560352
- Testing
- Dasatinib, Bortezomib, Dexamethasone
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.